All > Edmonton

CFI-402411 for Advanced Solid Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Advanced Solid TumorsCFI-402411 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing an investigational drug called CFI-402411 as a possible treatment for advanced solid tumors.

Eligible Conditions
  • Advanced Solid Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
JTX-8064
1
SRK-181
1
a PD-1 inhibitor

Study Objectives

4 Primary · 13 Secondary · Reporting Duration: 48 months

48 months
To assess best overall response of CFI-402411 monotherapy and in combination with pembrolizumab.
To assess duration of response of CFI-402411 monotherapy and in combination with pembrolizumab.
To assess overall response rates of CFI-402411 monotherapy and in combination with pembrolizumab.
To assess overall survival of CFI-402411 monotherapy and in combination with pembrolizumab.
To assess progression free survival of CFI-402411 monotherapy and in combination with pembrolizumab.
To assess the incidence of adverse events of CFI-402411 as a single agent and at the recommended phase 2 dose (RP2D).
To assess the incidence of adverse events with CFI-402411 in combination with pembrolizumab and at the RP2D.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab though Cmin.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through AUC.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Cmax.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through T1/2.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Tmax.
To evaluate the effect of CFI-402411 treatment on immune- or disease related biomarkers.
To examine best overall response rate in subjects treated at multiple dose levels of CFI-402411.
To examine progression free survival in subjects treated at multiple dose levels of CFI-402411.
To further assess the incidence of adverse events of CFI-402411.
To identify the maximum tolerated dose of single agent CFI-402411 alone and in combination with pembrolizumab.

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
JTX-8064
1
SRK-181
1
a PD-1 inhibitor

Side Effects for

Pembrolizumab+EP
54%Neutropenia
45%Anaemia
38%Nausea
34%Alopecia
31%Decreased appetite
29%Constipation
27%Fatigue
26%Thrombocytopenia
22%Leukopenia
21%Diarrhoea
20%Cough
17%Asthenia
17%Dyspnoea
16%Vomiting
14%Pyrexia
14%Dizziness
13%Arthralgia
13%Rash
13%Headache
12%Hypothyroidism
11%Insomnia
11%Pruritus
11%Back pain
10%Weight decreased
9%Hyponatraemia
9%Aspartate aminotransferase increased
8%Oedema peripheral
8%Upper respiratory tract infection
8%Alanine aminotransferase increased
8%Pneumonia
7%Abdominal pain
7%Blood creatinine increased
7%Hypokalaemia
7%Febrile neutropenia
6%Abdominal pain upper
6%Stomatitis
6%Dysgeusia
6%Erythema
6%Dry skin
5%Hyperthyroidism
5%Dyspepsia
5%Dysphagia
5%Chest pain
5%Blood alkaline phosphatase increased
5%Musculoskeletal pain
5%Hypertension
5%Nasopharyngitis
5%Musculoskeletal chest pain
5%Pain in extremity
4%Urinary tract infection
4%Hypotension
2%Death
2%Acute kidney injury
2%Pneumonitis
2%Pulmonary embolism
2%Atrial fibrillation
1%Neutropenic sepsis
1%Inappropriate antidiuretic hormone secretion
1%Diabetes mellitus
1%Hemiparesis
1%Transient ischaemic attack
1%Superior vena cava syndrome
1%Pneumothorax
1%Gastritis
1%Aortic aneurysm
1%Sepsis
1%Pleural infection
1%Infusion related reaction
1%Clostridium difficile colitis
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab+EP ARM group. Side effects include: Neutropenia with 54%, Anaemia with 45%, Nausea with 38%, Alopecia with 34%, Decreased appetite with 31%.

Trial Design

5 Treatment Groups

B1: Combination Escalation
1 of 5
A1: Monotherapy Escalation
1 of 5
A3: Monotherapy Expansion
1 of 5
A2: Monotherapy Biomarker
1 of 5
B2: Combination Expansion
1 of 5

Experimental Treatment

170 Total Participants · 5 Treatment Groups

Primary Treatment: CFI-402411 · No Placebo Group · Phase 1 & 2

B1: Combination EscalationExperimental Group · 2 Interventions: CFI-402411, Pembrolizumab · Intervention Types: Drug, Drug
A1: Monotherapy Escalation
Drug
Experimental Group · 1 Intervention: CFI-402411 · Intervention Types: Drug
A3: Monotherapy Expansion
Drug
Experimental Group · 1 Intervention: CFI-402411 · Intervention Types: Drug
A2: Monotherapy Biomarker
Drug
Experimental Group · 1 Intervention: CFI-402411 · Intervention Types: Drug
B2: Combination ExpansionExperimental Group · 2 Interventions: CFI-402411, Pembrolizumab · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 months

Who is running the clinical trial?

Treadwell Therapeutics, IncLead Sponsor
3 Previous Clinical Trials
133 Total Patients Enrolled
TIO Discovery EngineUNKNOWN
Johanna Bendell, DrPrincipal InvestigatorSarah Cannon
Omid Hamid, DrPrincipal InvestigatorThe Angeles Clinic, Los Angeles

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have received at least one systemic therapy for recurrent / metastatic disease.
You have a performance status of 0 or 1.
The patient must be receiving monotherapy with an antiretroviral drug.
You have a histological or cytological diagnosis of advanced solid malignancy that is refractory to or not a candidate for current standard treatment(s) and for whom no standard therapy is available.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top